Physician profile
Thomas G Stauss
NPI 1841267572
$33,715.46
in general payments reported to CMS, 2019-2025
26 companies · $1,055 in 2025
The $1,055 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,565 · 2020: $1,773 · 2021: $875 · 2022: $374 · 2023: $2,207 · 2024: $23K · 2025: $1,055.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $22K · Food and Beverage: $2,147 · Consulting Fee: $1,750 · Travel and Lodging: $216 · Gift: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $21,971.58 |
| Food and Beverage | $2,146.51 |
| Consulting Fee | $1,750.00 |
| Travel and Lodging | $215.66 |
| Gift | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genesys Orthopedics Systems, L.L.C. | $22,016.58 | 2023-2024 | Sacroiliac Joint Fusion System |
| Nevro Corp. | $7,548.15 | 2019-2024 | Senza |
| Southern Spine, LLC | $1,750.00 | 2023 | |
| Spinal Simplicity, LLC | $927.94 | 2025 | Ha Minuteman G3-R |
| Curonix LLC | $524.28 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $221.96 | 2020-2021 | |
| Abbott Laboratories | $148.31 | 2020-2021 | |
| Si-Bone, INC. | $66.61 | 2023 | |
| Painteq LLC | $66.14 | 2022-2024 | Painteq |
| Grt US Holding, INC. | $58.30 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $42.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $42.44 | 2019-2020 | |
| Abbvie INC. | $39.83 | 2022 | |
| Lilly USA, LLC | $36.98 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $32.88 | 2021-2025 | Xtampza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $29.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.71 | 2025 | Spravato |
| Vertiflex, INC. | $25.27 | 2019 | |
| Heron Therapeutics, INC. | $23.99 | 2025 | Zynrelef |
| Horizon Therapeutics Plc | $20.41 | 2021 | |
| Globus Medical, INC. | $18.90 | 2025 | Vyrsa V1 |
| Medtronic, INC. | $13.62 | 2023 | Synchromedii |
| Electronic Waveform Lab, INC. | $12.52 | 2020 | |
| Pfizer INC. | $12.01 | 2019 | |
| Foundation Fusion Solutions, LLC | $6.77 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.